Zobrazeno 1 - 10
of 93
pro vyhledávání: '"ditan"'
Autor:
Anderson CC, VanderPluym JH
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 17, Pp 1979-1993 (2023)
Christopher C Anderson,* Juliana H VanderPluym* Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA*These authors contributed equally to this workCorrespondence: Juliana H VanderPluym, Department of Neurology, Mayo Clinic, 13400 E S
Externí odkaz:
https://doaj.org/article/913b9d907362479a9e78574fb624bb53
Autor:
Simona Sacco, Christian Lampl, Faisal Mohammad Amin, Mark Braschinsky, Christina Deligianni, Derya Uludüz, Jan Versijpt, Anne Ducros, Raquel Gil-Gouveia, Zaza Katsarava, Paolo Martelletti, Raffaele Ornello, Bianca Raffaelli, Deirdre M. Boucherie, Patricia Pozo-Rosich, Margarita Sanchez-del-Rio, Alexandra Sinclair, Antoinette Maassen van den Brink, Uwe Reuter
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failur
Externí odkaz:
https://doaj.org/article/f2e139c79f47462bb7a320e0480913ae
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Roopa Satyanarayan Basutkar, Chris Elizabeth Vinod, Shruthi Jaya Saju, Bhavya Chebrolu, Sivasankaran Ponnusankar
Publikováno v:
Annals of Indian Academy of Neurology, Vol 24, Iss 2, Pp 155-163 (2021)
Background: The current target of migraine treatment is focused on Triptans. Lasmiditan, a non-vasoconstrictive and highly selective 5HT1F receptor agonist is a novel therapeutic discovery for migraine for patients with cardiovascular (CV) risk facto
Externí odkaz:
https://doaj.org/article/3ede3382aa634c53ab9e8c9849fe932d
Autor:
Richard B. Lipton, Louise Lombard, Dustin D. Ruff, John H. Krege, Li Shen Loo, Andrew Buchanan, Thomas E. Melby, Dawn C. Buse
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-15 (2020)
Abstract Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on mig
Externí odkaz:
https://doaj.org/article/da23bbe9f2134bc4a0a5ebd3697602f8
Autor:
Robert E. Shapiro, Helen M. Hochstetler, Ellen B. Dennehy, Rashna Khanna, Erin Gautier Doty, Paul H. Berg, Amaal J. Starling
Publikováno v:
The Journal of Headache and Pain, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background In addition to the increased risk for cardiovascular (CV) disease and CV events associated with migraine, patients with migraine can also present with a number of CV risk factors (CVRFs). Existing treatment options can be limited
Externí odkaz:
https://doaj.org/article/43acf2b853544c06a592c412abb84774
Autor:
Li Shen Loo, Jessica Ailani, Jack Schim, Simin Baygani, Hans-Peter Hundemer, Martha Port, John H. Krege
Publikováno v:
The Journal of Headache and Pain, Vol 20, Iss 1, Pp 1-11 (2019)
Abstract Objective To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications. Background While lasmiditan has been proven to be an effective acute treatment for migraine, its effe
Externí odkaz:
https://doaj.org/article/e17ff30540e948098b3ff112a023a7a4
Publikováno v:
The Journal of Headache and Pain, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies. Main body The development of ditans, gepants and anti-calcitonin gene-related pep
Externí odkaz:
https://doaj.org/article/2c6891d67c094cb6bf5a00d32939d7e2
Autor:
Gang Wan1, Fangyuan Gao2, Jialiang Chen3, Yuxin Li2, Mingfan Geng3, Le Sun3, Yao Liu2, Huimin Liu2, Xue Yang2, Rui Wang2, Ying Feng2 ann_fengying@sina.com, Xianbo Wang2 wangxb@ccmu.edu.cn, Wan, Gang4 (AUTHOR), Gao, Fangyuan5 (AUTHOR), Chen, Jialiang6 (AUTHOR), Li, Yuxin5 (AUTHOR), Geng, Mingfan6 (AUTHOR), Sun, Le6 (AUTHOR), Liu, Yao5 (AUTHOR), Liu, Huimin5 (AUTHOR)
Publikováno v:
BMC Cancer. 1/31/2017, Vol. 17, p1-11. 11p. 1 Diagram, 4 Charts, 2 Graphs.